Atlas Trials

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Clinical trial NCT06523049 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06523049
Sponsor
Hao Zeng
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell CarcinomaImmunotherapyMolecular Targeted Therapy
Start date
2024-08-01
Primary completion
2026-07-01
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.